Export

ATC codes: J01GB06
Indication
Inflammatory and other diseases of prostate ICD11 code: GA91.Z
INN
Amikacin
Medicine type
Chemical agent
Antibiotic groups
List type
Core
Formulations
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
EML status history
First added in 2017 (TRS 1006)
Changed in 2023 (TRS 1049)
Sex
Male
Age
Adolescents and adults
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Expert Committee recommendation
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.
EML recommendations: Inflammatory and other diseases of prostate
First choice
Second choice
mild to moderate
severe
First choice
ceftriaxone co-prescribed with amikacin
cefotaxime co-prescribed with amikacin
Second choice